<< Back to News

System Formulary Update
5-Aminosalicyclic Acid Derivatives

Situation

The 5-aminosalicyclic acid derivative class review and formulary standardization was approved at the October 2020 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: balsalazide, mesalamine (Apriso, Asacol HD, Canasa, Delzicol, Lialda, Pentasa, Rowasa, SfRowasa), olsalazine, sulfasalazine

 Assessment/Recommendation

Changes effective: Tuesday December 15, 2020

System P&T voted to include the following products on the UNC Health Medication Formulary:

• Mesalamine
  • Lialda tablet, delayed release: 1.2 g
  • Rowasa rectal enema: 4 g/60 mL
• Sulfasalazine
  • Tablet: 500 mg
  • Oral suspension: 100 mg/mL (extemporaneously prepared)

Note: Stock of these formulary products may vary at individual entities

As a result, the following products will be removed from the UNC Health Medication Formulary

• Balsalazide
• Mesalamine
  • Rectal suppository enema (Canasa)
  • Capsule, delayed release (Delzicol)
  • Tablet, delayed release (Asacol HD)
  • Capsule, extended release (Apriso)
  • Capsule, controlled release (Pentasa)
• Olsalazine
• Sulfasalazine

Non-formulary orders for balsalazide, mesalamine, olsalazine, and sulfasalazine will be converted according to a therapeutic interchange.